Cellular Senescence and COVID-19 Long-Hauler Syndrome

Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04903132

Enrollment

200

Registered

2021-05-26

Start date

2021-03-01

Completion date

2026-12-01

Last updated

2026-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV2 Infection

Brief summary

The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.

Detailed description

Assays for cellular senescence markers, SASP factors, inflammatory mediators, pro-fibrotic factors, and auto-antibodies in blood and urine will be conducted in patients who provide informed consent. Data will be related to subject age, date of COVID-19 infection, severity of that infection, current Long-Hauler Syndrome symptoms), physical examination findings, underlying conditions, and laboratory data. To understand if an association between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than controls in this pilot study.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Longhauler's Cohort - Inclusion Criteria: * Ability to give informed consent or LAR. * At least 18 years old. * Ability of subject or LAR to read and speak the English language. * Positive PCR or antibody test within 12 months of initial study visit. * Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.

Exclusion criteria

* Any potential participant who refuses medical record review. * Pregnant females. * Incarcerated individuals. * Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study. Control Cohort - Inclusion Criteria: * Ability to give informed consent * At least 18 years old * Ability of subject to read and speak the English language

Design outcomes

Primary

Measure	Time frame	Description
Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors	6 months	If a correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than age- and sex-matched controls (using archived samples) in this pilot study, a protocol will be submitted to the IRB for a trial in Long-Hauler Syndrome patients of senolytic drugs.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRyan T. Hurt, MD, PhD

Mayo Clinic

Outcome results